- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Understanding Clinical Nuance
Clinical nuance is one of the core tenets of value-based insurance design, which is one possible solution to alleviate the financial burden Americans face as they are asked to pay a greater percentage of their healthcare expenditures.
This article was collaboratively written by A. Mark Fendrick, MD, director of the V-BID Center, and several V-BID Center staff.
As Americans are asked to pay a greater percentage of their healthcare expenditures, cost-related nonadherence is an important and growing problem. A potential solution—Value-Based Insurance Design (VBID)—is built on the principle of lowering or removing financial barriers to essential, high-value clinical services and providers. VBID plans align patients’ out-of-pocket costs, such as copayments, with the value of services.
Clinical nuance is one of the core tenets of VBID. This concept recognizes 2 important facts about the provision of medical care: 1) medical services differ in the amount of health produced; and 2) the clinical benefit derived from a medical service depends on who is using it, who is delivering the service, and where it is being delivered.
To learn more about clinical nuance, view the video below, and visit
.
the Clinical Nuance initiative page
The Breakdown: Breast Cancer Research Awareness Day
August 19th 2025Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American Journal of Managed Care® breaks down the most recent advancements in breast cancer prevention, screening, and therapies.
Listen
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
